Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.52 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629569 | 0.98 | CTRB1 (0.53) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL4347938 | 0.89 | CTRB1 (0.44) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL461037 | 0.89 | CTRB1 (0.44) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL19447203 | 0.89 | FASN (0.58) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL13223295 | 0.85 | CTRB1 (0.47) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL15178886 | 0.83 | CTRB1 (0.40) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL20308653 | 0.82 | F2 (0.44) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL5501059 | 0.79 | CTRB1 (0.42) | CTRB1FASNF2PRSS1GRM2 | |
| SCHEMBL24163244 | 0.78 | CAPN1 (0.47) | — | |
| SCHEMBL13311356 | 0.77 | PARP1 (0.38) | CTRB1FASNF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-10314913-B2 | Polylactide compositions and uses thereof | UNIVERSITY OF GENEVA (CH) | 2019-06-11 | — | — | US | disclosed |
| US-10314913-B2 | Polylactide compositions and uses thereof | UNIVERSITY OF GENEVA (CH) | 2019-06-11 | — | — | US | disclosed |
| US-20180271984-A1 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | UNIVERSITY OF GENEVA (CH) | 2018-09-27 | — | — | US | disclosed |
| EP-3339348-A1 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | Universite De Geneve (CH) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339348-A1 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | Universite De Geneve (CH) | 2018-06-27 | — | — | EP | disclosed |
| US-9925267-B2 | Polylactide compositions and uses thereof | UNIVERSITY OF GENEVA (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9925267-B2 | Polylactide compositions and uses thereof | UNIVERSITY OF GENEVA (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9925267-B2 | Polylactide compositions and uses thereof | UNIVERSITY OF GENEVA (CH) | 2018-03-27 | — | — | US | disclosed |
| EP-1883665-B1 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | UNIV GENEVE (CH) | 2017-10-11 | — | — | EP | disclosed |
| EP-1758948-B1 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KK (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-7465779-B2 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof | CANON KABUSHIKI KAISHA (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1281766-B1 | Process for producing polyester, process for producing substituted alpha-hydroxy acid, and Clostridium beijerinckii strain HICA432 | CANON KK (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | CANON KABUSHIKI KAISHA (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1883665-A2 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2008-02-06 | — | — | EP | disclosed |
| US-7273734-B2 | Process for producing a polyester | CANON KABUSHIKI KAISHA (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273734-B2 | Process for producing a polyester | CANON KABUSHIKI KAISHA (JP) | 2007-09-25 | — | — | US | disclosed |
| WO-2007012979-A2 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | UNIVERSITE DE GENEVE (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012979-A2 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | UNIVERSITE DE GENEVE (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060247414-A1 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof | CANON KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314913-B2 | Polylactide compositions and uses thereof | LPXN, PUF60, DDOST | CTRB1 1787/4885FASN 298/4885F2 2177/4885 |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | FAR1, ACSL4, ACAD11 | CTRB1 3279/4885FASN 12/4885F2 2624/4885 |
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | HDHD5, HAO2, ALAD | CTRB1 2087/4885FASN 763/4885F2 189/4885 |
| US-20180271984-A1 | POLYLACTIDE COMPOSITIONS AND USES THEREOF | LPXN, PUF60, DDOST | CTRB1 1787/4885FASN 298/4885F2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.